Genomic and epigenomic roadmap to understand otosclerosis
Official title: The genomic and epigenomic landscape of otosclerosis
Funded at University of Arizona · NIH-11492144 · Data updated 2026-11-12
This NIH grant aims to map the genetic and epigenetic factors behind otosclerosis to better understand why this bone disease causes hearing loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | March 12, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $85,000 |
| NIH project number | 3R01DC021686-02S1 |
| Project ID | NIH-11492144 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with otosclerosis or a family history of the condition who are willing to participate in genetic and epigenetic analyses.
✕Less likely to help
Individuals without otosclerosis or a relevant family history are unlikely to benefit from this study.
What this research studies
Otosclerosis affects the tiny bones in the ear and often progresses with age, especially in women, leading to hearing problems. The project will study DNA and epigenetic changes in a large group of people with otosclerosis and related families to identify genes involved. By using advanced genomic techniques, researchers hope to reveal how genetic and epigenetic factors contribute to the disease. The findings could pave the way for better diagnosis and future therapies that target the underlying biology rather than just the symptoms.
Why it matters
Potential benefit: If successful, the work could improve diagnosis and lead to new approaches that address the root causes of otosclerosis, potentially slowing or altering its progression.
How similar studies have gone: Previous studies suggest genetic involvement in otosclerosis; this project builds on existing cohorts to identify novel genes and mechanisms.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Schrauwen, Isabelle Veerle Suzanne — University of Arizona
- Study coordinator: Schrauwen, Isabelle Veerle Suzanne
Related research
Other NIH-funded projects on the same topics.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Mining safety training that connects research to practice for Western miners
A patient-facing overview of a U.S. mining safety program that partners universities and mining operators to improve training, safety practices, and outcomes for mine workers in the Western United States.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Mobile platform using AI to screen for oral cancer in low-resource communities
A low-cost, AI-powered mobile tool helps frontline healthcare workers screen for oral cancer and triage patients in communities with limited access to specialists.
-
A new optical method to image skin cancers using synthetic waves
A small grant is funding the development and testing of tissue-mimicking skin phantoms to improve non-invasive imaging of skin cancers.
-
MRI-guided precision care for infants with cleft palate
We’re exploring how MRI can help tailor early care for babies with cleft palate to support better speech outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.